FDA Inspection
SEAGEN INC.SEAGEN INC. – FDA Inspection, May 1, 2017
Record Details
This FDA Inspection record concerns SEAGEN INC., with an inspection on May 1, 2017, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · ac55515f-4f67-4756-8f43-566d0f1b6cd8
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1011478
- FDA center
- Human Drugs
- Project area
- Bioresearch Monitoring
- Outcome
- Form 483 issued
FDA Citations
2- 21 CFR 600.80(c)(1)(i)Reporting Requirements - 15-day alert
- 21 CFR 600.80(b)Review of Adverse Experiences - SOPs
Full citation text and observation details available on the Dashboard.
Other FDA inspections of SEAGEN INC.
10| Date | Classification | Office | Project area |
|---|---|---|---|
| May 13, 2025 | VAI | Seattle District Office | Drug Quality Assurance |
| November 1, 2024 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| May 2, 2024 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| January 24, 2020 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| October 4, 2019 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
Other documents for SEAGEN INC.
- FDA Inspection 1272265 - 2025-05-13
- FDA Inspection 1253880 - 2024-11-01
- FDA Inspection 1236983 - 2024-05-02
- FDA Inspection 1119141 - 2020-01-24
- FDA Inspection 1107250 - 2019-10-04
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.